



#16
Super Amend/E
PATENT APPLICATION
1/26/02 MW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

ENDL et al.

Art Unit: 1644

Application No: 09/343,406

Examiner: M. DiBrino

Filed: June 30, 1999

Attorney Dkt. No. 100564-09014

RECEIVED

JAN 08 2002

TECH CENTER 1600/2900

For: ANTIGEN-SPECIFIC ACTIVATED T-LYMPHOCYTES, DETECTION AND USE

SUPPLEMENTARY AMENDMENT PURSUANT TO 37 CFR § 1.111

Commissioner for Patents
Washington, D.C. 20231

January 4, 2002

Sir:

This paper is filed as a supplementary response to the Office Action dated July 31, 2001, along with the Amendment filed December 31, 2001. Applicants respectfully request entry of the following amendments without prejudice.

IN THE SPECIFICATION:

Please amend the specification as follows without prejudice.

Page 7, line 23,-Page 8, lines 1-15:

E1
The present invention also particularly concerns peptide variants whose sequence does not completely correspond to the above-mentioned amino acid sequences but which have the same or closely related "anchor positions". In this connection the terms "anchor position" means an amino acid residue essential for binding to a MHC molecule in particular to a MHC molecule of classes DR3, DR4 or DQ. The anchor positions for